Announcements Trials
Browse Landscape

Phase

Phase 1 86Phase 1/2 13Phase 2 4Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 290Prostatic Neoplasms 192Neoplasm Metastasis 154Multiple Myeloma 147Colorectal Neoplasms 123Lung Neoplasms 104Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 88Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 80Stomach Neoplasms 76Small Cell Lung Carcinoma 72Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 66Pain 66Uterine Cervical Neoplasms 64Carcinoma, Renal Cell 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Advanced Cancer × Clear all
NCT02743494 2025-11-18

CheckMate 577

Bristol-Myers Squibb

Phase 3 Completed
794 enrolled 13 charts 1 FDA

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡